Back to search

National and Kapodistrian University of Athens

Μελέτη του ρόλου του ανοσοποιητικού συστήματος στην παθογένεση της νόσου Alzheimer σε διαγονιδιακά ποντίκια-μοντέλα της νόσου

Abstract

dc:description

Increasing evidence has suggested that brain inflammation can play a significant role in Alzheimer’s disease (AD) pathogenesis. Identifying key molecules that regulate the crosstalk between the immune and the central nervous system can provide potential therapeutic targets. TNF-α is a pleiotropic cytokine that exerts its functions through engagement of two receptors, TNFRI and TNFRII. In the brain, TNF-α is mainly expressed by microglia and astrocytes. Previous in vivo and in vitro studies concerning the role of TNF-α in Alzheimer’s disease have provided ambiguous results, implying that TNF-α can have both beneficial and detrimental effects in AD. In the present study we support the involvement of TNF-α in beta-amyloid (Αβ) production as well as in Αβ clearance in the 5XFAD transgenic mouse model of AD. Genetic deletion of TNF-α decreases amyloid plaque formation in 5XFAD mice by lowering Aβ generation through the reduction of β-secretase (BACE1), the crucial enzyme in the amyloidogenic APP (amyloid precursor protein) processing pathway leading to Αβ accumulation. Moreover, elimination of TNF-α expression results in decreased astrocytic and microglial activation and reduced Αβ uptake by phagocytes, further implying that decreased amyloid deposition in the 5XFAD/TNF-α-/- mouse brain is attributed to decreased Αβ production rather than enhanced cell-mediated Αβ clearance. Our data confirm the role of TNF-α signaling in the regulation of APP processing and Αβ production and support TNF-α targeting as a potential therapeutical approach for Alzheimer’s disease. The central role of TNF-α in chronic inflammatory diseases like rheumatoid arthritis (RA) has led to the development of anti-TNF-α therapeutics that have been proved very effective in RA therapy. Taking into consideration recent studies reporting that anti-TNF-α therapy or RA itself can modulate AD pathology, although the underlying mechanism is unclear, we generated and analyzed double transgenic 5XFAD/Tg197 AD/TNF mice that develop amyloid deposits and inflammatory arthritis induced by huTNF-α expression. 5XFAD/Tg197 mice express huTNF-α both in the periphery and the brain and show significantly decreased amyloid deposition, robust brain inflammation characterized by diffused gliosis and increased perivascular macrophages and infiltrating leukocytes, as well as compromised neuronal integrity. To evaluate whether the observed brain phenotype is attributed to peripheral or brain huTNF-α, we treated 5XFAD/Tg197 mice systemically with infliximab anti-huTNF-α antibody that does not cross the blood-brain-barrier and inhibits arthritis. Peripheral infliximab treatment significantly lowers huTNF-α in the circulation but not in the brain and reverses the amyloid and brain inflammatory phenotype, leading to increased amyloid deposition, decreased glial activation, reduced blood-derived immune cells and restored neuronal integrity. Given that 5XFAD/Tg197 AD/TNF mice show a further enhancement of blood-derived immune populations in the brain compared to Tg197, we propose enhanced Αβ clearance by these cell types in addition to activated microglia as the underlying mechanism that mediates the reduction of amyloid pathology in 5XFAD/Tg197 mice. Our findings demonstrate for the first time that peripheral TNF-α can strongly modulate the amyloid phenotype by regulating blood-derived and local brain inflammatory cell populations, thus underlining the significance of a TNF-dependent periphery-to-brain immune communication pathway in Alzheimer’s disease. Overall, the present study indicates TNF-α as a mediator that can affect multiple aspects of Alzheimer’s disease, which should be taken into consideration in the possible future treatment of AD patients with anti-TNF-α agents.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2017

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Paouri, Evangelia
  • Παούρη, Ευαγγελία

Subjects

dc:subject × 22

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/40462

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Paouri, Evangelia; Παούρη, Ευαγγελία. Μελέτη του ρόλου του ανοσοποιητικού συστήματος στην παθογένεση της νόσου Alzheimer σε διαγονιδιακά ποντίκια-μοντέλα της νόσου. National and Kapodistrian University of Athens, 2017. http://hdl.handle.net/10442/hedi/40462